NCT/Study#

NCT04535557 /

MOBOCERTINIB-EAP

An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer patients with EGFR exon20 insertion mutations

An expanded access protocol for mobocertinib in refractory Non-Small Cell Lung Cancer
patients with EGFR exon20 insertion mutations

DISEASE GROUP:
Phase 1
current phase:
NA
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: